Premium
Substances that can trigger activation of the alternative pathway of complement have anti‐melanoma activity in mice
Author(s) -
Cooper Peter D.,
Sim Robert B.
Publication year - 1984
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910330520
Subject(s) - alternative complement pathway , zymosan , melanoma , complement system , guinea pig , complement factor b , pharmacology , immunology , complement (music) , ratón , medicine , biology , chemistry , cancer research , antibody , biochemistry , in vitro , complementation , gene , phenotype
Abstract Intraperitoneal (i.p.) injection of substances that can ignite the alternative pathway of complement, namely isolated human C3b or C3(H 2 O), guinea‐pig C3(H 2 O) or cobra venom factor, or conventionally prepared zymosan, will reproducibly and very significantly increase the mean survival time of C57BL mice previously inoculated i.p. with melanoma cells. The effect is greater at higher doses and earlier post‐inoculation (p.i.) administration, but the substances are active at low doses (30–100 μg/mouse) if given early enough. It is likely that C3b or C3(H 2 O) was the previously unidentified anti‐tumour factor activated in serum by S. aureus treatment or serum fractionation and described elsewhere. Activation of the alternative pathway of complement appears to have potential interest for cancer therapy.